Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Researchers Warn Against Targeting Only One Viral Gene for SARS-CoV-2 Detection by RT-PCR Due to Mutation in N Gene

By HospiMedica International staff writers
Posted on 31 Aug 2020
Researchers have warned against targeting only one viral gene when carrying out reverse transcriptase-polymerase chain reaction (RT-PCR) testing for the SARS-CoV-2 virus, according to a report by News Medical.

A team of researchers at the Chan Zuckerberg Biohub (San Francisco, CA, USA) carried out a study to demonstrate that a mutation had occurred in the N gene of the SARS-CoV-2 virus that impaired the annealing of a commonly used RT-PCR primer. More...


Testing for SARS-CoV-2 generally involves using RT-PCR to test for the viral genome in respiratory samples and is performed using primer pairs that target more than one viral gene. The protocol involves assays that target the N gene and the E gene in SAR-VoV-2, and other groups commonly use these assays. However, the WHO has recommended that “in areas where the COVID-19 virus is widely spread, a simpler algorithm might be adopted in which, for example, screening by RT-PCR of a single discriminatory target is considered sufficient.”

In July, the researchers had identified clustering of 35 samples that showed poor assay performance for the N gene, but not the E gene. In order to identify the potential reasons for this, the team carried out a study that identified a nucleotide change in an N gene primer sequence that disrupted annealing and amplification, thus reducing diagnostic sensitivity. Based on their findings, the researchers have suggested the routine use of at least two targets when testing for SARS-CoV-2 using RT-PCR, even in areas where transmission rates are high, according to the News Medical report.

According to the researchers, their findings suggest that even in areas where community spread of SARS-CoV-2 is high, mutations can occur that impair recognition of RT-PCR primers and reduce diagnostic sensitivity, leading to under-diagnosis if laboratories used only one target for SARS-CoV-2 detection.

Related Links:
Chan Zuckerberg Biohub


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ultrasound Needle Guidance System
SonoSite L25
Endoscopy Display
E190
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.